58 reports

  • Bladder cancer
  • Economic burden of bladder cancer

About Bladder Cancer Therapeutics The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the...

  • Bladder Cancer
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bladder Cancer Risk Factors
  • lists two of the major risks factors for bladder cancer.

EpiCast Report: Bladder Cancer - Epidemiology Forecast to 2025 Summary Bladder cancer is a commonly diagnosed cancer and causes significant numbers of cancer deaths worldwide (Parkin, 2008; Ploeg et al., 2009). The major risk factors for bladder cancer are exposure to smoking and occupational risk factors such as exposure...

  • Bladder Cancer
  • Japan
  • United Kingdom
  • United States
  • Forecast

Global Bladder Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Bladder Cancer
  • France
  • United States
  • World
  • Forecast
  • EXPECTED KEY UPDATES TO THE BLADDER CANCER COMPETITIVE LANDSCAPE
  • SEVERAL KEY EVENTS WILL DRIVE CHANGES TO THE BLADDER CANCER MARKET LANDSCAPE.

Bladder Cancer: Dynamic Market Forecast to 2026 Summary Bladder cancer is a rapidly evolving field in which new developments are constantly influencing the market landscape. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the bladder cancer space, including...

  • Bladder Cancer
  • United States
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Roche Group

Bladder Cancer 2017

7595 8355 6456

Bladder Cancer 2017 ##.

  • Bladder Cancer
  • Therapy
  • United States
  • Forecast

Bladder Cancer: Update Bulletin ### [February 2018] This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market.

  • Bladder Cancer
  • Therapy
  • Vaccine
  • United States
  • Supply
  • BLADDER CANCER STAGING SYSTEM
  • BLADDER CANCER RISK FACTORS

OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2025 Summary Bladder cancer is a urologic malignancy arising primarily from epithelial cells lining the bladder. In the vast majority of cases (>90%), bladder cancer manifests as transitional (urothelial) cell carcinoma (TCC). The remaining...

  • Bladder Cancer
  • United States
  • Demand
  • Merck & Co., Inc.
  • OncoGenex Pharmaceuticals, Inc.

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • France
  • Germany
  • United States
  • Market Size

Bladder cancer -Epidemiology Forecast to 2027 ##.

  • Bladder Cancer
  • France
  • Germany
  • Italy
  • Spain

Europe Bladder Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Bladder Cancer
  • Europe
  • France
  • Germany
  • Forecast

Bladder cancer - Market Insight, Epidemiology and Market Forecast - 2027 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • United States
  • Market Shares

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • France
  • Germany
  • Italy
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • United States
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • Japan
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • Italy
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • Germany
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • France
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • United Kingdom
  • Market Size

Bladder Cancer Phase ## Clinical Trials, 2016 ##.

  • Bladder Cancer
  • Cancer
  • Pathology
  • Spain
  • Market Size
  • STAGES AND HISTOPATHOLOGY OF BLADDER CANCER
  • Major Histopathology in Bladder Cancer

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Bladder Cancer in 18 Major Markets Bladder Cancer is cancer arising in the urinary bladder, generally from urothelial cells. It is the fourth most common cancer in males and the ninth most common in females. While Bladder Cancer is associated with significant...

  • Bladder Cancer
  • Cancer
  • Pathology

" Target Atlas in Bladder Cancer: A Competitive Outlook" is a one-of-a-kind, authoritative target analyzer tool, integrated with drug pipeline information covering commercial developments of molecular drug targets in bladder cancer from ## compan

  • Bladder Cancer
  • Cancer
  • LEADING TREATMENTS FOR BLADDER CANCER
  • BLADDER CANCER STAGING SYSTEMS

Opportunity Analyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2017 Summary The bladder cancer market has remained largely unchanged in the past 10-20 years. However, significant expansion is expected starting in 2016, with the introduction of several new therapies that are projected to fuel market...

  • Bladder Cancer
  • United States
  • GlobalData's company
  • Roche Group
  • Spectrum Pharmaceuticals, Inc.
  • Bladder Cancer Overview
  • Bladder Cancer Treatment Drugs Market Overview

China’s demand for Low Density Polyethylene (LDPE) has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export,...

  • Bladder Cancer
  • China
  • Demand
  • Trade
  • Sanofi-Synthelabo Inc.
  • Bladder Cancer Overview
  • Bladder Cancer Treatment Drugs Market Overview

This study focuses on China’s Lubricating Oil Additive industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of...

  • Bladder Cancer
  • China
  • Demand
  • Market Size
  • Trade
  • CHAPTER III BLADDER CANCER TREATMENT DRUGS INDUSTRY ASSESSMENTS
  • CHAPTER III BLADDER CANCER TREATMENT DRUGS INDUSTRY ASSESSMENTS

However, the sales volume of anti-bladder cancer drugs increase annually.

  • Bladder Cancer
  • China
  • Bristol-Myers Squibb China Inc Ltd
  • Sanofi-Synthelabo Inc.
  • Schering-Plough Corporation

Drug analysis: Cyramza

9091 10000 7727

Drug analysis: Cyramza Product Profiles Cyramza : Colorectal cancer (CRC) Cyramza : Hepatocellular carcinoma (HCC) Cyramza : Bladder cancer Cyramza : Non-small cell lung cancer (NSCLC) Cyramza : Gastric cancer LIST OF FIGURES Figure ##: Cyramza f

  • Bladder Cancer
  • European Union
  • Japan
  • United States
  • Supply
  • LATEST CLINICAL TRIALS NEWS ON BLADDER CANCER
  • TOP COMPANIES PARTICIPATING IN BLADDER CANCER THERAPEUTICS CLINICAL TRIALS

Bladder Cancer Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Bladder Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Bladder Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Bladder...

  • Bladder Cancer
  • Clinical Trial
  • Oncology
  • World
  • Product Initiative
  • MUSCLE INVASIVE BLADDER CANCER (MIBC)
  • Unaccomplished Trials of Muscle Invasive Bladder Cancer (MIBC)

Muscle Invasive Bladder Cancer (MIBC) Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Muscle Invasive Bladder Cancer (MIBC) Global Clinical Trials Review, H1, 2018" provides an overview of Muscle Invasive Bladder Cancer (MIBC) clinical trials scenario.This report...

  • Bladder Cancer
  • Chemotherapy
  • Therapy
  • World
  • Product Initiative
  • Latest Clinical Trials News on Bladder Cancer
  • BLADDER CANCER THERAPEUTICS, GLOBAL, CLINICAL TRIALS BY PHASE (%), 2017*

Bladder Cancer Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Bladder Cancer Global Clinical Trials Review, H1, 2017" provides an overview of Bladder Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Bladder Cancer. Report includes...

  • Bladder Cancer
  • Clinical Trial
  • Oncology
  • World
  • Merck & Co., Inc.
  • Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview
  • BIOLOGIC FOR SUPERFICIAL BLADDER CANCER - DRUG PROFILE

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H2 2016’, provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder...

  • Bladder Cancer
  • Oncology
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.